Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03142451 · ClinicalTrials.gov registry record · Phase 3
A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea
A Phase 3 study, sponsored by Vyne Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 751
- Enrollment target
NCT03142451 is a Phase 3 study that has completed, run by Vyne Therapeutics. The registered enrollment target is 751 participants.
The verdict
NCT03142451, a Phase 3 study, has completed, sponsored by Vyne Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 751 participants
- Enrollment target
Study Summary
The primary objectives of this study are to determine the efficacy and safety of FMX103 1.5% minocycline foam applied topically once daily for 12 weeks in the treatment of rosacea.
Interventions
- DRUG Vehicle foam
- DRUG FMX103 minocycline foam 1.5%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 751 participants |
| Start Date | 2017-06-02 |
| Est. Completion | 2018-09-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03142451
The ClinicalTrials.gov registry entry for NCT03142451 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 751 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vyne Therapeutics, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vehicle foam is the first listed.
NCT03142451 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03142451 about?
NCT03142451 is a clinical study titled "A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea". The primary objectives of this study are to determine the efficacy and safety of FMX103 1.5% minocycline foam applied topically once daily for 12 weeks in the treatment of rosacea.
What is the current status of trial NCT03142451?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 751 participants. The study started on 2017-06-02. Estimated completion is 2018-09-28.
What interventions are being tested in trial NCT03142451?
The interventions under investigation include: Vehicle foam (DRUG), FMX103 minocycline foam 1.5% (DRUG).
Who is sponsoring clinical trial NCT03142451?
This trial is sponsored by Vyne Therapeutics, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.